Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lifecore Biomedical, Inc. \De\ (LFCR) Invested Capital (2016 - 2025)

Historic Invested Capital for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to $131.8 million.

  • Lifecore Biomedical, Inc. \De\'s Invested Capital fell 309.67% to $131.8 million in Q2 2025 from the same period last year, while for May 2025 it was $131.8 million, marking a year-over-year decrease of 309.67%. This contributed to the annual value of $131.8 million for FY2025, which is 309.67% down from last year.
  • According to the latest figures from Q2 2025, Lifecore Biomedical, Inc. \De\'s Invested Capital is $131.8 million, which was down 309.67% from $127.2 million recorded in Q1 2025.
  • In the past 5 years, Lifecore Biomedical, Inc. \De\'s Invested Capital ranged from a high of $366.8 million in Q2 2021 and a low of $75.3 million during Q3 2023
  • Moreover, its 5-year median value for Invested Capital was $135.0 million (2023), whereas its average is $177.1 million.
  • Per our database at Business Quant, Lifecore Biomedical, Inc. \De\'s Invested Capital tumbled by 5734.06% in 2023 and then soared by 6870.08% in 2024.
  • Quarter analysis of 5 years shows Lifecore Biomedical, Inc. \De\'s Invested Capital stood at $279.6 million in 2021, then plummeted by 39.17% to $170.1 million in 2022, then tumbled by 44.57% to $94.3 million in 2023, then skyrocketed by 34.44% to $126.8 million in 2024, then grew by 3.96% to $131.8 million in 2025.
  • Its last three reported values are $131.8 million in Q2 2025, $127.2 million for Q1 2025, and $126.8 million during Q4 2024.